Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

1978
2025

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1983 1
1985 2
1986 3
1987 1
1988 5
1989 8
1990 7
1991 5
1992 4
1993 15
1994 12
1995 8
1996 14
1997 20
1998 11
1999 26
2000 30
2001 26
2002 33
2003 43
2004 37
2005 31
2006 48
2007 50
2008 35
2009 38
2010 50
2011 51
2012 39
2013 73
2014 64
2015 70
2016 81
2017 79
2018 76
2019 89
2020 105
2021 87
2022 78
2023 73
2024 59
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

1,425 results

Results by year

Filters applied: . Clear all
Page 1
B-cell non-Hodgkin lymphomas.
Silkenstedt E, Salles G, Campo E, Dreyling M. Silkenstedt E, et al. Lancet. 2024 May 4;403(10438):1791-1807. doi: 10.1016/S0140-6736(23)02705-8. Epub 2024 Apr 10. Lancet. 2024. PMID: 38614113 Review.
B-cell lymphomas occur with an incidence of 20 new cases per 100 000 people per year in high-income countries. ...This Seminar provides an overview of the pathobiology, classification, and prognostication of B-cell non-Hodgkin lymphomas and summarises
B-cell lymphomas occur with an incidence of 20 new cases per 100 000 people per year in high-income countries. ...This Seminar
CAR T-cell therapy for B-cell lymphoma.
Denlinger N, Bond D, Jaglowski S. Denlinger N, et al. Curr Probl Cancer. 2022 Feb;46(1):100826. doi: 10.1016/j.currproblcancer.2021.100826. Epub 2021 Dec 25. Curr Probl Cancer. 2022. PMID: 35012754 Free PMC article. Review.
Chimeric antigen receptor-modified (CAR) T-cell therapy targeting CD19 has revolutionized the treatment of relapsed or refractory B-cell lymphomas. Based on unprecedented response rates and durability of response in high risk B-cell lymphoma pat …
Chimeric antigen receptor-modified (CAR) T-cell therapy targeting CD19 has revolutionized the treatment of relapsed or refractory B- …
Treatment of relapsed/refractory paediatric aggressive B-cell non-Hodgkin lymphoma.
Moleti ML, Testi AM, Foà R. Moleti ML, et al. Br J Haematol. 2020 Jun;189(5):826-843. doi: 10.1111/bjh.16461. Epub 2020 Mar 6. Br J Haematol. 2020. PMID: 32141616 Free article. Review.
Aggressive B-cell non-Hodgkin lymphoma (B-NHL) accounts for 60% of NHL in children/adolescents. In newly diagnosed Burkitt lymphoma and diffuse large B-cell lymphoma, short intensive multiagent chemotherapy is
Aggressive B-cell non-Hodgkin lymphoma (B-NHL) accounts for 60% of NHL in children/adolescents. In
Defining and treating high-grade B-cell lymphoma, NOS.
Olszewski AJ, Kurt H, Evens AM. Olszewski AJ, et al. Blood. 2022 Sep 1;140(9):943-954. doi: 10.1182/blood.2020008374. Blood. 2022. PMID: 34525177 Free article. Review.
High-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), is a recently introduced diagnostic category for aggressive B-cell lymphomas. ...Recent analyses using gene expression profiling (GEP) revealed that up to 15% of tumors cur …
High-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), is a recently introduced diagnostic category for a
Plasmablastic lymphoma: An update.
Bailly J, Jenkins N, Chetty D, Mohamed Z, Verburgh ER, Opie JJ. Bailly J, et al. Int J Lab Hematol. 2022 Sep;44 Suppl 1(Suppl 1):54-63. doi: 10.1111/ijlh.13863. Int J Lab Hematol. 2022. PMID: 36074710 Free PMC article. Review.
Plasmablastic lymphoma (PBL) is a highly aggressive B cell non-Hodgkin lymphoma frequently associated with immunosuppression, particularly human immunodeficiency virus (HIV) infection. ...Laboratory features in PBL may overlap with …
Plasmablastic lymphoma (PBL) is a highly aggressive B cell non-Hodgkin lymphoma frequently …
Diffuse large B-cell lymphoma.
Martelli M, Ferreri AJ, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA. Martelli M, et al. Crit Rev Oncol Hematol. 2013 Aug;87(2):146-71. doi: 10.1016/j.critrevonc.2012.12.009. Epub 2013 Jan 30. Crit Rev Oncol Hematol. 2013. PMID: 23375551 Review.
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy in adults accounting for 31% of all NHL in Western Countries. ...Disseminated extranodal disease is less frequent, and one third of patients have systemic symptoms. Overall, DLBCLs a …
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy in adults accounting for 31% of all NHL in …
Double hit and double expressors in lymphoma: Definition and treatment.
Riedell PA, Smith SM. Riedell PA, et al. Cancer. 2018 Dec 15;124(24):4622-4632. doi: 10.1002/cncr.31646. Epub 2018 Sep 25. Cancer. 2018. PMID: 30252929 Free article. Review.
Emerging biologic subsets and new prognostic markers are significantly and adversely affecting curability after standard chemoimmunotherapy for aggressive B-cell lymphomas. The identification of concurrent MYC and B-cell CLL/lymphoma 2 (B …
Emerging biologic subsets and new prognostic markers are significantly and adversely affecting curability after standard chemoimmunotherapy …
MALT lymphoma: epidemiology, clinical diagnosis and treatment.
Violeta Filip P, Cuciureanu D, Sorina Diaconu L, Maria Vladareanu A, Silvia Pop C. Violeta Filip P, et al. J Med Life. 2018 Jul-Sep;11(3):187-193. doi: 10.25122/jml-2018-0035. J Med Life. 2018. PMID: 30364585 Free PMC article. Review.
Primary gastric lymphoma (PGL) represents a rare pathology, which can be easily misdiagnosed because of unspecific symptoms of the digestive tract. Histologically, PGL can vary from indolent marginal zone B-cell lymphoma of the mucosa-associated lympho …
Primary gastric lymphoma (PGL) represents a rare pathology, which can be easily misdiagnosed because of unspecific symptoms of the di …
Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma.
Abramson JS. Abramson JS. Transfus Med Rev. 2020 Jan;34(1):29-33. doi: 10.1016/j.tmrv.2019.08.003. Epub 2019 Aug 29. Transfus Med Rev. 2020. PMID: 31677848 Review.
Anti-CD19 CAR T-cells currently represent transformational therapy for relapsed/refractory aggressive B-cell lymphomas where durable remissions can be induced in patients with previously incurable chemotherapy-refractory disease. ...Efficacy and safety data f …
Anti-CD19 CAR T-cells currently represent transformational therapy for relapsed/refractory aggressive B-cell lymphomas …
Hepatic Lymphoma Diagnosis.
Choi WT, Gill RM. Choi WT, et al. Surg Pathol Clin. 2018 Jun;11(2):389-402. doi: 10.1016/j.path.2018.02.003. Epub 2018 Mar 21. Surg Pathol Clin. 2018. PMID: 29751882 Review.
Systemic hematopoietic disorders may present on liver biopsy, and rare cases of primary hepatic lymphoma (PHL) may be encountered. Hepatopathologists must be familiar with the full spectrum of hematopoietic disorders involving the liver and be prepared to exclude benign mi …
Systemic hematopoietic disorders may present on liver biopsy, and rare cases of primary hepatic lymphoma (PHL) may be encountered. He …
1,425 results